NGEN Stock Overview
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage.
NervGen Pharma Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CA$1.62|
|52 Week High||CA$3.33|
|52 Week Low||CA$1.52|
|1 Month Change||-17.77%|
|3 Month Change||-19.40%|
|1 Year Change||-27.03%|
|3 Year Change||24.62%|
|5 Year Change||n/a|
|Change since IPO||-6.90%|
Recent News & Updates
|NGEN||CA Pharmaceuticals||CA Market|
Return vs Industry: NGEN exceeded the Canadian Pharmaceuticals industry which returned -66.7% over the past year.
Return vs Market: NGEN underperformed the Canadian Market which returned -7.3% over the past year.
|NGEN Average Weekly Movement||11.4%|
|Pharmaceuticals Industry Average Movement||11.8%|
|Market Average Movement||9.9%|
|10% most volatile stocks in CA Market||18.2%|
|10% least volatile stocks in CA Market||3.8%|
Stable Share Price: NGEN is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: NGEN's weekly volatility (11%) has been stable over the past year.
About the Company
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. Its lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer’s disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage.
NervGen Pharma Fundamentals Summary
|NGEN fundamental statistics|
Is NGEN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|NGEN income statement (TTM)|
|Cost of Revenue||CA$0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.32|
|Net Profit Margin||0.00%|
How did NGEN perform over the long term?See historical performance and comparison
Is NGEN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NGEN?
Other financial metrics that can be useful for relative valuation.
|What is NGEN's n/a Ratio?|
Price to Book Ratio vs Peers
How does NGEN's PB Ratio compare to its peers?
|NGEN PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
LOVE Cannara Biotech
CRDL Cardiol Therapeutics
MMEN MedMen Enterprises
NGEN NervGen Pharma
Price-To-Book vs Peers: NGEN is expensive based on its Price-To-Book Ratio (9.6x) compared to the peer average (1.6x).
Price to Earnings Ratio vs Industry
How does NGEN's PE Ratio compare vs other companies in the CA Pharmaceuticals Industry?
Price-To-Book vs Industry: NGEN is expensive based on its Price-To-Book Ratio (9.6x) compared to the Canadian Pharmaceuticals industry average (0.9x)
Price to Book Ratio vs Fair Ratio
What is NGEN's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||9.6x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate NGEN's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of NGEN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate NGEN's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate NGEN's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
How is NervGen Pharma forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if NGEN's forecast earnings growth is above the savings rate (1.6%).
Earnings vs Market: Insufficient data to determine if NGEN's earnings are forecast to grow faster than the Canadian market
High Growth Earnings: Insufficient data to determine if NGEN's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if NGEN's revenue is forecast to grow faster than the Canadian market.
High Growth Revenue: NGEN is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NGEN's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has NervGen Pharma performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NGEN is currently unprofitable.
Growing Profit Margin: NGEN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NGEN is unprofitable, and losses have increased over the past 5 years at a rate of 46.2% per year.
Accelerating Growth: Unable to compare NGEN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NGEN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (39.8%).
Return on Equity
High ROE: NGEN has a negative Return on Equity (-192.7%), as it is currently unprofitable.
Discover strong past performing companies
How is NervGen Pharma's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: NGEN's short term assets (CA$12.2M) exceed its short term liabilities (CA$2.9M).
Long Term Liabilities: NGEN's short term assets (CA$12.2M) exceed its long term liabilities (CA$241.0K).
Debt to Equity History and Analysis
Debt Level: NGEN is debt free.
Reducing Debt: NGEN has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NGEN has sufficient cash runway for 11 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: NGEN is forecast to have sufficient cash runway for 3 months based on free cash flow estimates, but has since raised additional capital.
Discover healthy companies
What is NervGen Pharma current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|NervGen Pharma Dividend Yield vs Market|
|Company (NervGen Pharma)||n/a|
|Market Bottom 25% (CA)||2.1%|
|Market Top 25% (CA)||6.1%|
|Industry Average (Pharmaceuticals)||2.6%|
|Analyst forecast in 3 Years (NervGen Pharma)||n/a|
Notable Dividend: Unable to evaluate NGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NGEN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NGEN's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as NGEN has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Bill Radvak (59 yo)
Mr. William Joseph Radvak, also known as Bill, BASc, serves as Interim Chief Executive Officer at NervGen Pharma Corp. since September 23, 2022. He served as Chief Executive Officer at Regency Gold Corp. s...
CEO Compensation Analysis
|Bill Radvak's Compensation vs NervGen Pharma Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||CA$98k||CA$98k|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||CA$131k||CA$131k|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||CA$158k||CA$135k|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||n/a||n/a|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||CA$48k||CA$48k|
Compensation vs Market: Bill's total compensation ($USD71.14K) is below average for companies of similar size in the Canadian market ($USD179.12K).
Compensation vs Earnings: Bill's compensation has been consistent with company performance over the past year.
Experienced Board: NGEN's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: NGEN insiders have only sold shares in the past 3 months.
Recent Insider Transactions
|19 Aug 22||SellCA$11,275||William Radvak||Individual||5,500||CA$2.05|
|29 Nov 21||BuyCA$208,000||William Radvak||Individual||80,000||CA$2.60|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 44.3%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
NervGen Pharma Corp.'s employee growth, exchange listings and data sources
- Name: NervGen Pharma Corp.
- Ticker: NGEN
- Exchange: TSXV
- Founded: 2017
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: CA$95.060m
- Shares outstanding: 58.68m
- Website: https://www.nervgen.com
Number of Employees
- NervGen Pharma Corp.
- 2955 Virtual Way
- Suite 480
- British Columbia
- V5M 4X6
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|NGEN||TSXV (TSX Venture Exchange)||Yes||Common Shares||CA||CAD||Mar 2019|
|NGEN.F||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||Mar 2019|
|9UA||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Mar 2019|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/26 00:00|
|End of Day Share Price||2022/09/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.